Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease.

drug protocol number
RPC01-3201
drug sponsor
Celgene
drug study
Ozanimod HCl
drug trial site
KAUH-J
drug status
Ongoing
drug phase